Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
Ono Pharmaceutical’s immuno-oncology star Opdivo (nivolumab) saw its sales dwindle 13% to 90.1 billion yen in the year ended March 2018, despite a 45% volume increase, as it took a full-year blow from a 50% emergency price slashed imposed in…
To read the full story
Related Article
- Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
- Ono to Boost Oncology Reps to Prep for Opdivo Label Expansions
May 11, 2018
- Opdivo’s Half-Year Sales Sag as 50% Price Cut Takes Toll: Ono
November 7, 2017
- Ono Lifts Half-Year Guidance on Opdivo Boon
October 27, 2017
- Opdivo Drives Ono to Record Profits in FY2016
May 15, 2017
BUSINESS
- Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
- Gilead Files Trodelvy-Keytruda Combo for 1L TNBC in Japan
April 24, 2026
- Co-Promotions Dominate in Oncology, Diabetes Alliances: Fuji Keizai
April 24, 2026
- Medii, Pediatric Neurology Society Build System to Support Elevidys Use
April 24, 2026
- Oncolys’ OBP-301 Wins US Fast Track Designation
April 24, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…